• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用虚拟筛选设计HIV-1整合酶核心结构域抑制剂

Design of inhibitors of the HIV-1 integrase core domain using virtual screening.

作者信息

Regon Preetom, Gogoi Dhrubajyoti, Rai Ashok Kumar, Bordoloi Manabjyoti, Bezbaruah Rajib Lochan

机构信息

Centre for Bioinformatics Studies, Dibrugarh University, Dibrugarh, Assam.

DBT-Bioinformatics Infrastructure Facility, Biotechnology Division, CSIR-North East Institute of Science and Technology (CSIR), Jorhat, Assam.

出版信息

Bioinformation. 2014 Feb 19;10(2):76-80. doi: 10.6026/97320630010076. eCollection 2014.

DOI:10.6026/97320630010076
PMID:24616558
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3937579/
Abstract

Acquired immunodeficiency syndrome (AIDS) is a disease of the human immune system caused by the human immunodeficiency virus (HIV). The integrase (IN) enzyme of HIV interacts with several cellular and viral proteins during the integration process. Thus, it represents an appropriate target for antiretroviral drugs (ARVs). We performed virtual screening of database compounds and designed analogues using Elvitegravir (EVG) as a standard compound. The 378 screened compounds were retrieved from ZINC, ChemSpider, PubChem, and ChemBank Chemical Databases based on chemical similarity and literature searches related to the structure of EVG. The Physiochemical properties, Bioactivity, Toxicity and Absorption, Distribution, Metabolism and Excretion of Molecules (ADME) of these compounds were predicted and docking Experiments were conducted using Molegro Virtual Docker software. The docking and ADME suggested very significant results in regard to EVG. The MolDock and Rerank scores were used to analyze the results. The compounds ZINC26507991 (-84.22), Analogue 9 (-68.49), ZINC20731658 (-66.79), ZINC00210363 (-43.44) showed better binding orientation with IN receptor model with respect to EVG (182.52). The ZINC26507991 has showed significant ADME result.

摘要

获得性免疫缺陷综合征(艾滋病)是一种由人类免疫缺陷病毒(HIV)引起的人类免疫系统疾病。HIV的整合酶(IN)在整合过程中与多种细胞和病毒蛋白相互作用。因此,它是抗逆转录病毒药物(ARV)的一个合适靶点。我们以埃替格韦(EVG)为标准化合物,对数据库化合物进行虚拟筛选并设计类似物。根据与EVG结构相关的化学相似性和文献检索,从ZINC、ChemSpider、PubChem和ChemBank化学数据库中检索出378种筛选化合物。预测了这些化合物的物理化学性质、生物活性、毒性以及分子的吸收、分布、代谢和排泄(ADME),并使用Molegro Virtual Docker软件进行对接实验。对接和ADME实验得出了与EVG相关的非常显著的结果。使用MolDock和重新排序分数来分析结果。化合物ZINC26507991(-84.22)、类似物9(-68.49)、ZINC20731658(-66.79)、ZINC00210363(-43.44)相对于EVG(182.52)与IN受体模型显示出更好的结合方向。ZINC26507991显示出显著的ADME结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a14/3937579/8db82aa63210/97320630010076F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a14/3937579/8db82aa63210/97320630010076F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a14/3937579/8db82aa63210/97320630010076F1.jpg

相似文献

1
Design of inhibitors of the HIV-1 integrase core domain using virtual screening.利用虚拟筛选设计HIV-1整合酶核心结构域抑制剂
Bioinformation. 2014 Feb 19;10(2):76-80. doi: 10.6026/97320630010076. eCollection 2014.
2
Structure-based virtual screening toward the discovery of novel inhibitors for impeding the protein-protein interaction between HIV-1 integrase and human lens epithelium-derived growth factor (LEDGF/p75).基于结构的虚拟筛选以发现新型抑制剂,阻止 HIV-1 整合酶与人晶状体上皮衍生生长因子(LEDGF/p75)之间的蛋白质-蛋白质相互作用。
J Biomol Struct Dyn. 2018 Sep;36(12):3199-3217. doi: 10.1080/07391102.2017.1384400. Epub 2017 Oct 23.
3
Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137).新型人类免疫缺陷病毒整合酶抑制剂埃替格韦(JTK-303/GS-9137)的广泛抗逆转录病毒活性及耐药情况
J Virol. 2008 Jan;82(2):764-74. doi: 10.1128/JVI.01534-07. Epub 2007 Oct 31.
4
Development of Potential Inhibitors for Human T-lymphotropic Virus Type I Integrase Enzyme: A Molecular Modeling Approach.人类嗜T淋巴细胞病毒I型整合酶潜在抑制剂的开发:一种分子建模方法。
Curr Comput Aided Drug Des. 2024;20(1):72-86. doi: 10.2174/1573409919666230419082839.
5
Examining structural analogs of elvitegravir as potential inhibitors of HIV-1 integrase.研究埃替拉韦的结构类似物作为潜在的 HIV-1 整合酶抑制剂。
Arch Virol. 2014 Aug;159(8):2069-80. doi: 10.1007/s00705-014-2038-y. Epub 2014 Mar 19.
6
Effect of Ethanol on the Metabolic Characteristics of HIV-1 Integrase Inhibitor Elvitegravir and Elvitegravir/Cobicistat with CYP3A: An Analysis Using a Newly Developed LC-MS/MS Method.乙醇对HIV-1整合酶抑制剂埃替格韦及埃替格韦/考比司他与CYP3A代谢特征的影响:采用新开发的LC-MS/MS方法进行的分析
PLoS One. 2016 Feb 12;11(2):e0149225. doi: 10.1371/journal.pone.0149225. eCollection 2016.
7
Therapy-Emergent Drug Resistance to Integrase Strand Transfer Inhibitors in HIV-1 Patients: A Subgroup Meta-Analysis of Clinical Trials.HIV-1患者中对整合酶链转移抑制剂出现的治疗性耐药:临床试验的亚组荟萃分析
PLoS One. 2016 Aug 17;11(8):e0160087. doi: 10.1371/journal.pone.0160087. eCollection 2016.
8
Structural requirements for potential HIV-integrase inhibitors identified using pharmacophore-based virtual screening and molecular dynamics studies.使用基于药效团的虚拟筛选和分子动力学研究确定的潜在HIV整合酶抑制剂的结构要求。
Mol Biosyst. 2016 Mar;12(3):982-93. doi: 10.1039/c5mb00767d.
9
Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.在使用卡替拉韦、比克替拉韦、多替拉韦和艾维雷韦的患者来源的临床分离株中出现的选择性耐药谱。
Retrovirology. 2018 Aug 17;15(1):56. doi: 10.1186/s12977-018-0440-3.
10
New scaffolds of natural origin as Integrase-LEDGF/p75 interaction inhibitors: virtual screening and activity assays.新型天然来源支架作为整合酶-LDGF/p75 相互作用抑制剂:虚拟筛选和活性测定。
Eur J Med Chem. 2013 Oct;68:405-11. doi: 10.1016/j.ejmech.2013.07.025. Epub 2013 Aug 9.

引用本文的文献

1
Docking Screens for Novel Ligands Conferring New Biology.用于赋予新生物学特性的新型配体的对接筛选
J Med Chem. 2016 May 12;59(9):4103-20. doi: 10.1021/acs.jmedchem.5b02008. Epub 2016 Mar 15.

本文引用的文献

1
Insights from the docking analysis of biologically active compounds from plant Litsea Genus as potential COX-2 inhibitors.作为潜在COX-2抑制剂的樟科木姜子属植物生物活性化合物对接分析的见解。
Bioinformation. 2012;8(17):812-5. doi: 10.6026/97320630008812. Epub 2012 Sep 11.
2
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.恩曲他滨、替诺福韦、考比司他与艾维雷韦、恩曲他滨、替诺福韦复方制剂用于初治 HIV-1 感染:一项随机、双盲、III 期临床试验,48 周后结果分析。
Lancet. 2012 Jun 30;379(9835):2439-2448. doi: 10.1016/S0140-6736(12)60917-9.
3
Crystal structure of the HIV-1 integrase core domain in complex with sucrose reveals details of an allosteric inhibitory binding site.HIV-1 整合酶核心结构域与蔗糖复合物的晶体结构揭示了变构抑制结合位点的细节。
FEBS Lett. 2010 Apr 16;584(8):1455-62. doi: 10.1016/j.febslet.2010.03.016. Epub 2010 Mar 16.
4
Elvitegravir, an oral HIV integrase inhibitor, for the potential treatment of HIV infection.埃替格韦,一种口服HIV整合酶抑制剂,用于潜在治疗HIV感染。
Curr Opin Investig Drugs. 2009 Feb;10(2):190-200.
5
MolDock: a new technique for high-accuracy molecular docking.MolDock:一种用于高精度分子对接的新技术。
J Med Chem. 2006 Jun 1;49(11):3315-21. doi: 10.1021/jm051197e.
6
ZINC--a free database of commercially available compounds for virtual screening.锌数据库——一个可用于虚拟筛选的商业可用化合物免费数据库。
J Chem Inf Model. 2005 Jan-Feb;45(1):177-82. doi: 10.1021/ci049714+.
7
Virtual screening of chemical libraries.化学文库的虚拟筛选
Nature. 2004 Dec 16;432(7019):862-5. doi: 10.1038/nature03197.
8
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.药物研发环境中估算溶解度和渗透性的实验与计算方法。
Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):3-26. doi: 10.1016/s0169-409x(00)00129-0.
9
Side-chain flexibility in proteins upon ligand binding.配体结合后蛋白质侧链的灵活性。
Proteins. 2000 May 15;39(3):261-8. doi: 10.1002/(sici)1097-0134(20000515)39:3<261::aid-prot90>3.0.co;2-4.
10
Retroviral DNA integration.逆转录病毒DNA整合
Microbiol Mol Biol Rev. 1999 Dec;63(4):836-43, table of contents. doi: 10.1128/MMBR.63.4.836-843.1999.